AI-Driven Strategy Exits Haemonetics Position for 89% Gain After One Year

An AI-driven investment strategy has closed its position in medical technology firm Haemonetics Corporation (HAE) for a total return of nearly 89% after holding the stock for exactly one year, according to a report from Investing.com. The trade was executed by the publication's "Mid-Cap Movers" model, which algorithmically selects U.S. stocks.

Haemonetics' Year-Long Rally

The model first identified Haemonetics in September 2025 at a price of $54.54 per share, the report stated. The position was exited on September 1, 2026, at $103.07 per share, locking in a gain of 88.98% over the 365-day holding period.

Several fundamental catalysts underpinned the stock's performance. Key drivers included:

• A non-exclusive commercial supply deal with CSL Plasma for its NexSys PCS collection devices, which sent shares up nearly 16% in a single session on August 18.
• A fiscal first-quarter earnings beat, with adjusted earnings per share of $1.14 on revenue of $339.4 million.
• Subsequent price target increases from analysts at BTIG and Raymond James following the results.

Ad

Strategy and Market Context

The "Mid-Cap Movers" strategy focuses on identifying 20 promising U.S. stocks each month with market capitalizations between $2 billion and $10 billion, according to the publication. The model captured most of the stock's significant run-up before rotating out of the position during its monthly rebalancing.

The report also noted strong performance from other catalyst-driven value and mid-cap strategies. A separate model focused on Warren Buffett's portfolio holdings highlighted steel producer Nucor (NUE), which gained approximately 4.2% this week after the company raised prices for hot-rolled coil steel and reported a quarterly earnings beat.